Educating Patients About First-Line Treatment Options for Advanced Renal-Cell Carcinoma

Video Library —September 13, 2021
Laura Wood, RN, MSN, OCN
Cleveland Clinic Taussig Cancer Center
Cleveland, OH
Megan Price, MSN, APRN, FNP-C
Baylor Charles A. Sammons Cancer Center
Dallas, TX
Virginia Seery, CRNP, MSN
Beth Israel Deaconess Medical Center, Harvard Medical School Teaching Hospital, Boston, MA
Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their approach to conversations with patients and families regarding first-line therapy for advanced renal-cell carcinoma. They also describe what resources they share with patients to help them after the initial consultation.
Related Articles
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
New Developments on Prognostic Markers for Patients With Early Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials.
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country